It is a broadly described annual report of Beximco Pharmaceuticals Limited in the year of 2016. Net sales during January-June 2016 grew by 13.1% to reach Taka. 7,069.0 million. Sales in the domestic market increased by 13.6%, while export increased by 5.3%. Pre and post-tax profit for the six months amounted to Taka. 1,320.7 million and Taka. 993.8 million, respectively. The pre-tax profit recorded an increase of 20.8% as compared to the same six months (un-audited) period of the prior year. EPS stood at Tk. 2.57.
The Board of Directors recommended 5% cash (Tk. 0.50 per share) as the final dividend in addition to 5% stock dividend (5 shares for every 100 shares held) and 10% cash (Tk. 1.00 per share) dividend already paid as an interim dividend. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.
More Annual Report of Beximco Pharmaceuticals Limited :
- Annual Report 2001 of Beximco Pharmaceuticals Limited
- Annual Report 2002 of Beximco Pharmaceuticals Limited
- Annual Report 2003 of Beximco Pharmaceuticals Limited
- Annual Report 2004 of Beximco Pharmaceuticals Limited
- Annual Report 2005 of Beximco Pharmaceuticals Limited
- Annual Report 2006 of Beximco Pharmaceuticals Limited
- Annual Report 2007 of Beximco Pharmaceuticals Limited
- Annual Report 2008 of Beximco Pharmaceuticals Limited
- Annual Report 2009 of Beximco Pharmaceuticals Limited
- Annual Report 2010 of Beximco Pharmaceuticals Limited
- Annual Report 2011 of Beximco Pharmaceuticals Limited
- Annual Report 2012 of Beximco Pharmaceuticals Limited
- Annual Report 2013 of Beximco Pharmaceuticals Limited
- Annual Report 2014 of Beximco Pharmaceuticals Limited
- Auditors’ Report 2015 of Beximco Pharmaceuticals Limited
- Annual Report 2016 of Beximco Pharmaceuticals Limited
- Auditors’ Report 2017 of Beximco Pharmaceuticals Limited
